Lexicon Pharmaceuticals (NASDAQ:LXRX) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a research note published on Wednesday.

A number of other equities research analysts also recently commented on the stock. SVB Leerink initiated coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. They issued an outperform rating and a $5.00 price objective for the company. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 23rd.

Lexicon Pharmaceuticals Trading Up 2.4 %

Shares of LXRX stock opened at $1.74 on Wednesday. Lexicon Pharmaceuticals has a twelve month low of $0.92 and a twelve month high of $3.79. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07. The business’s 50 day moving average is $2.10 and its two-hundred day moving average is $1.74. The company has a market capitalization of $428.46 million, a P/E ratio of -2.10 and a beta of 1.38.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 137.53%. Equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cantor Fitzgerald L. P. acquired a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $25,000. TIAA Trust National Association acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter worth approximately $29,000. Principal Securities Inc. purchased a new position in Lexicon Pharmaceuticals in the 4th quarter valued at approximately $33,000. Commonwealth Equity Services LLC raised its holdings in Lexicon Pharmaceuticals by 160.9% during the third quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 24,400 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 22,043 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.